U.S. Markets closed

Cesca Therapeutics Announces the Launch of its PXP™ System for Automated Processing of Bone Marrow Cells

RANCHO CORDOVA, Calif., July 16, 2018 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (“Cesca” or the “Company”) (KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that its device subsidiary, ThermoGenesis®, has launched its PXP System for the rapid processing of autologous bone marrow cells in the point-of-care setting, such as surgical centers or clinics.

“The commercial launch of our novel PXP System is significant, as it addresses many of the shortcomings of currently-available systems, most notably, red blood cell contamination in the resulting cell concentrate that is thought to diminish the efficacy of cell based treatments,” said Chris Xu, PhD, chief executive officer of Cesca Therapeutics. “PXP allows clinicians to rapidly achieve very high stem and progenitor cell recovery rates with negligible RBC contamination – typically less than 2% of the starting sample. The on-time commercial launch of PXP serves to further solidify our position as a leading innovator in the field of cellular processing, and together with our CAR-TXpress™ and related X-Series™ systems, comprises what we believe is the most advanced and clinically differentiated portfolio of cellular processing solutions available today.”

The ThermoGenesis PXP System is an automated, closed system that harvests a precise volume of cell concentrate from a sample of bone marrow aspirate. PXP can generate a concentration of bone marrow in less than 20 minutes, with consistently high mononuclear cell (MNC) and CD34+ progenitor cell recovery rates and greater than 98% depletion of contaminating RBCs. Processing data is captured using ThermoGenesis’ proprietary DataTrak™ software to assist with Good Manufacturing Practice (GMP) process monitoring and reporting information.

For more information, please visit: www.thermogenesis.com.

About Cesca Therapeutics Inc.        
Cesca Therapeutics Inc. (the “Company”) develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. Its device division, ThermoGenesis Corp., provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. The Company is developing an automated, functionally-closed CAR-TXpress™ platform to streamline the manufacturing process for the emerging CAR-T immunotherapy market.

Company Contact:
Cesca Therapeutics Inc.
Wendy Samford
916-858-5191
ir@cescatherapeutics.com

Investor Contact:
Rx Communications
Paula Schwartz
917-322-2216
pschwartz@rxir.com